Defining and managing imatinib resistance
MJ Mauro - ASH Education Program Book, 2006 - ashpublications.org
While imatinib is highly effective therapy, with improving prospects over time for sustained
remission and potential to severely limit or eliminate disease progression and …
remission and potential to severely limit or eliminate disease progression and …
Imatinib mesylate
CF Waller - Small Molecules in Oncology, 2014 - Springer
Abstract Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …
Imatinib mesylate
CF Waller - Small molecules in hematology, 2018 - Springer
Abstract Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …
Therapy options in imatinib failures
P Ramirez, JF DiPersio - The Oncologist, 2008 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the mechanisms that result in resistance to imatinib in CML patients. Employ the …
Describe the mechanisms that result in resistance to imatinib in CML patients. Employ the …
Imatinib mesylate
CF Waller - Small Molecules in Oncology, 2009 - Springer
Abstract IMATINIB MESYLATE (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly
referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer …
referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer …
Resistance to imatinib: mutations and beyond
P La Rosée, MW Deininger - Seminars in hematology, 2010 - Elsevier
Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in
vitro even prior to the first reports of clinical resistance in patients with chronic myeloid …
vitro even prior to the first reports of clinical resistance in patients with chronic myeloid …
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of …
HA Bradeen, CA Eide, T O'Hare, KJ Johnson, SG Willis… - Blood, 2006 - ashpublications.org
Abstract BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors
with activity against many imatinib mesylate–resistant BCR-ABL kinase domain (KD) …
with activity against many imatinib mesylate–resistant BCR-ABL kinase domain (KD) …
Resistance to imatinib: mechanisms and management
M Deininger - Journal of the National Comprehensive Cancer …, 2005 - jnccn.org
Imatinib, a specific small molecule inhibitor of the Abl kinase, has become the standard drug
therapy for chronic myelogenous leukemia in all phases. More than 80% of newly …
therapy for chronic myelogenous leukemia in all phases. More than 80% of newly …
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib
B Stein, BD Smith - Clinical therapeutics, 2010 - Elsevier
Background: Imatinib has been found to substantially improve outcomes in patients with
chronic myeloid leukemia (CML) compared with previously available therapies. However, its …
chronic myeloid leukemia (CML) compared with previously available therapies. However, its …
Strategies for overcoming imatinib resistance in chronic myeloid leukemia
L Kujawski, M Talpaz - Leukemia & lymphoma, 2007 - Taylor & Francis
Imatinib was the first treatment for chronic myeloid leukemia (CML) that specifically targeted
the causative BCR-ABL oncoprotein, and represented a major therapeutic advance in this …
the causative BCR-ABL oncoprotein, and represented a major therapeutic advance in this …